keyword
MENU ▼
Read by QxMD icon Read
search

Price transparency

keyword
https://www.readbyqxmd.com/read/28929871/japanese-healthcare-fostering-competition-and-controlling-costs
#1
James H Tiessen, Ken Kato
Japan's universal healthcare system is relatively inexpensive, provides accessible services, and was established nearly 10 years before Canada's. Two aspects of Japan's system are particularly interesting. The first is that there is active competition for patients between a variety of hospital providers, which can be privately or publicly owned. This competition is based on service quality because prices are set centrally. The second feature is that these prices are adjusted biannually by a National Council, the Chuikyo, that includes payers (employers), providers, and third-party experts in public negotiations...
July 2017: Healthcare Management Forum
https://www.readbyqxmd.com/read/28917469/prior-authorizations-for-dermatologic-medications-an-american-academy-of-dermatology-survey-of-us-dermatology-providers-and-staff
#2
Aaron M Secrest, Maryam M Asgari, Arianne S Kourosh, John S Barbieri, Joerg Albrecht
No abstract text is available yet for this article.
October 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28892524/research-and-development-spending-to-bring-a-single-cancer-drug-to-market-and-revenues-after-approval
#3
Vinay Prasad, Sham Mailankody
Importance: A common justification for high cancer drug prices is the sizable research and development (R&D) outlay necessary to bring a drug to the US market. A recent estimate of R&D spending is $2.7 billion (2017 US dollars). However, this analysis lacks transparency and independent replication. Objective: To provide a contemporary estimate of R&D spending to develop cancer drugs. Design, Setting, and Participants: Analysis of US Securities and Exchange Commission filings for drug companies with no drugs on the US market that received approval by the US Food and Drug Administration for a cancer drug from January 1, 2006, through December 31, 2015...
September 11, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28874405/pediatric-price-transparency-time-to-come-out-of-the-dark
#4
Kirsten Nieto, Christopher Moriates
No abstract text is available yet for this article.
September 5, 2017: Hospital Pediatrics
https://www.readbyqxmd.com/read/28874404/pediatric-price-transparency-still-opaque-with-opportunities-for-improvement
#5
Laura J Faherty, Charlene A Wong, Jordyn Feingold, Joan Li, Robert Town, Evan Fieldston, Rachel M Werner
OBJECTIVES: Price transparency is gaining importance as families' portion of health care costs rise. We describe (1) online price transparency data for pediatric care on children's hospital Web sites and state-based price transparency Web sites, and (2) the consumer experience of obtaining an out-of-pocket estimate from children's hospitals for a common procedure. METHODS: From 2015 to 2016, we audited 45 children's hospital Web sites and 38 state-based price transparency Web sites, describing availability and characteristics of health care prices and personalized cost estimate tools...
September 5, 2017: Hospital Pediatrics
https://www.readbyqxmd.com/read/28859183/association-between-patient-value-systems-and-physician-and-practice-attributes-available-online
#6
Jamie L Welshhans, Jeffrey J Harmon, Ira Papel, Richard Gentile, Devinder Mangat, Patrick Byrne, Ryan M Collar
Importance: The relative value of facial plastic surgeon personal and practice attributes is relevant to the broader health care system because of increasing out-of-pocket expenses to patients. Objective: To determine the relative value of specific facial plastic surgeon personal and practice attributes available online from the perspective of patients. Design, Setting, and Participants: This study consisted of an electronic survey sent to patients by email using choice-based conjoint analysis; surveys were sent between December 2015 and March 2016...
August 31, 2017: JAMA Facial Plastic Surgery
https://www.readbyqxmd.com/read/28836222/the-implementation-of-managed-entry-agreements-in-central-and-eastern-europe-findings-and-implications
#7
Alessandra Ferrario, Diāna Arāja, Tomasz Bochenek, Tarik Čatić, Dávid Dankó, Maria Dimitrova, Jurij Fürst, Ieva Greičiūtė-Kuprijanov, Iris Hoxha, Arianit Jakupi, Erki Laidmäe, Olga Löblová, Ileana Mardare, Vanda Markovic-Pekovic, Dmitry Meshkov, Tanja Novakovic, Guenka Petrova, Maciej Pomorski, Dominik Tomek, Luka Voncina, Alan Haycox, Panos Kanavos, Patricia Vella Bonanno, Brian Godman
BACKGROUND: Managed entry agreements (MEAs) are a set of instruments to facilitate access to new medicines. This study surveyed the implementation of MEAs in Central and Eastern Europe (CEE) where limited comparative information is currently available. METHOD: We conducted a survey on the implementation of MEAs in CEE between January and March 2017. RESULTS: Sixteen countries participated in this study. Across five countries with available data on the number of different MEA instruments implemented, the most common MEAs implemented were confidential discounts (n = 495, 73%), followed by paybacks (n = 92, 14%), price-volume agreements (n = 37, 5%), free doses (n = 25, 4%), bundle and other agreements (n = 19, 3%), and payment by result (n = 10, >1%)...
August 23, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28817296/patients-views-on-price-shopping-and-price-transparency
#8
Hannah L Semigran, Rebecca Gourevitch, Anna D Sinaiko, David Cowling, Ateev Mehrotra
OBJECTIVES: Driven by the growth of high deductibles and price transparency initiatives, patients are being encouraged to search for prices before seeking care, yet few do so. To understand why this is the case, we interviewed individuals who were offered access to a widely used price transparency website through their employer. STUDY DESIGN: Qualitative interviews. METHODS: We interviewed individuals enrolled in a preferred provider organization product through their health plan about their experience using the price transparency tool (if they had done so), their past medical experiences, and their opinions on shopping for care...
June 1, 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/28812229/economics-and-cost-effectiveness-of-multiple-sclerosis-therapies-in-the-usa
#9
REVIEW
Daniel M Hartung
Multiple sclerosis (MS) is a disabling, chronic disease that imposes a significant economic burden on patients and the US healthcare system. The largest cost component for individuals with MS are prescription drugs, specifically disease-modifying therapies (DMTs). Despite an increase in the number and diversity of DMTs over the past 10 years, acquisition costs for all DMTs have escalated dramatically at rates substantially higher than medical inflation. Currently, costs for most DMTs exceed $70,000 a year. Recent cost-effectiveness studies suggest the cost for nearly all DMTs exceeds generally accepted thresholds for what is considered a good value in the USA, even after factoring expected rebates...
August 15, 2017: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://www.readbyqxmd.com/read/28772164/multiple-criteria-decision-analysis-mcda-for-evaluating-new-medicines-in-health-technology-assessment-and-beyond-the-advance-value-framework
#10
Aris Angelis, Panos Kanavos
Escalating drug prices have catalysed the generation of numerous "value frameworks" with the aim of informing payers, clinicians and patients on the assessment and appraisal process of new medicines for the purpose of coverage and treatment selection decisions. Although this is an important step towards a more inclusive Value Based Assessment (VBA) approach, aspects of these frameworks are based on weak methodologies and could potentially result in misleading recommendations or decisions. In this paper, a Multiple Criteria Decision Analysis (MCDA) methodological process, based on Multi Attribute Value Theory (MAVT), is adopted for building a multi-criteria evaluation model...
September 2017: Social Science & Medicine
https://www.readbyqxmd.com/read/28751712/activation-of-mitophagy-leads-to-decline-in-mfn2-and-loss-of-mitochondrial-mass-in-fuchs-endothelial-corneal-dystrophy
#11
Anne-Sophie Benischke, Shivakumar Vasanth, Takashi Miyai, Kishore Reddy Katikireddy, Tomas White, Yuming Chen, Adna Halilovic, Marianne Price, Francis Price, Paloma B Liton, Ula V Jurkunas
Human corneal endothelial cells (HCEnCs) are terminally differentiated cells that have limited regenerative potential. The large numbers of mitochondria in HCEnCs are critical for pump and barrier function required for corneal hydration and transparency. Fuchs Endothelial Corneal Dystrophy (FECD) is a highly prevalent late-onset oxidative stress disorder characterized by progressive loss of HCEnCs. We previously reported increased mitochondrial fragmentation and reduced ATP and mtDNA copy number in FECD. Herein, carbonyl cyanide m-chlorophenyl hydrazone (CCCP)-induced mitochondrial depolarization decreased mitochondrial mass and Mfn2 levels, which were rescued with mitophagy blocker, bafilomycin, in FECD...
July 27, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28742372/health-care-price-transparency-and-communication-implications-for-radiologists-and-patients-in-an-era-of-expanding-shared-decision-making
#12
Gelareh Sadigh, Ruth C Carlos, Elizabeth A Krupinski, Carolyn C Meltzer, Richard Duszak
OBJECTIVE: The purpose of this article is to review the literature on communicating transparency in health care pricing, both overall and specifically for medical imaging. Focus is also placed on the imperatives and initiatives that will increasingly impact radiologists and their patients. CONCLUSION: Most Americans seek transparency in health care pricing, yet such discussions occur in fewer than half of patient encounters. Although price transparency tools can help decrease health care spending, most are used infrequently and most lack information about quality...
July 25, 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28741264/why-are-diabetes-medications-so-expensive-and-what-can-be-done-to-control-their-cost
#13
REVIEW
Laura N McEwen, Sarah Stark Casagrande, Shihchen Kuo, William H Herman
PURPOSE OF REVIEW: The purposes of this study were to describe how medication prices are established, to explain why antihyperglycemic medications have become so expensive, to show trends in expenditures for antihyperglycemic medications, and to highlight strategies to control expenditures in the USA. RECENT FINDINGS: In the U.S., pharmaceutical manufacturers set the prices for new products. Between 2002 and 2012, expenditures for antihyperglycemic medications increased from $10 billion to $22 billion...
September 2017: Current Diabetes Reports
https://www.readbyqxmd.com/read/28740622/drug-pricing-and-reimbursement-information-management-processes-and-decision-making-in-the-global-economy
#14
Dimitrios Tsourougiannis
Background: Cost-containment initiatives are re-shaping the pharmaceutical business environment and affecting market access as well as pricing and reimbursement decisions. Effective price management procedures are too complex to accomplish manually. Prior to February 2013, price management within Astellas Pharma Europe Ltd was done manually using an Excel database. The system was labour intensive, slow to update, and prone to error. An innovative web-based pricing information management system was developed to address the shortcomings of the previous system...
2017: Journal of Market Access & Health Policy
https://www.readbyqxmd.com/read/28734684/factors-influencing-list-prices-for-radiologists-services
#15
Andrew B Rosenkrantz, Wenyi Wang, Arvind Vijayasarathi, Richard Duszak
PURPOSE: To identify factors associated with list price variation for radiologists' services. METHODS: The 2014 Medicare Physician and Other Supplier Public Use File was used to identify submitted charges ("list prices") and payments for radiologists' services (ie, not hospital service charges). Charge-to-payment ratios were computed for individual radiologists as a measure of excess charges. Numerous radiologist-level factors identifiable using publicly available data sets were explored...
July 20, 2017: Journal of the American College of Radiology: JACR
https://www.readbyqxmd.com/read/28681277/availability-and-pricing-new-medicines-in-ireland-reflections-and-reform
#16
Paul K Gorecki
This paper argues that the current method of determining the availability and pricing of new medicines for public reimbursement in Ireland likely results in too large a share of public healthcare expenditure allocated to medicines. Resources are misallocated. Welfare is lowered. In contrast to some other areas of public healthcare, patients exercise 'voice' rather than 'exit' concerning the public provision of high-cost new medicines. Setting publicly agreed cost-effectiveness thresholds, with clear predictable criteria for when the cost-effectiveness thresholds can be exceeded, would contribute to the creation of a more appropriate new medicine decision-making framework...
July 5, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28679809/challenges-of-measuring-quality-of-community-based-programs-for-seriously-ill-individuals-and-their-families
#17
Joan M Teno, Rebecca Anhang Price, Lena K Makaroun
For many individuals and their families, acknowledging and confronting a serious illness such as cancer or advanced heart failure is a sentinel life event. From a health policy perspective, many individuals confronting such illnesses are high-need, high-cost patients who are increasingly cared for by community-based programs that may have competing goals: improving quality and reducing costs. Providing care to high-need, high-cost patients tests a health care system's ability to coordinate care and adapt to highly variable disease trajectories that could result in improved health for some, sudden and unexpected death for others, and a prolonged period of functional impairment for the majority...
July 1, 2017: Health Affairs
https://www.readbyqxmd.com/read/28655365/grade-evidence-to-decision-etd-framework-for-coverage-decisions
#18
Elena Parmelli, Laura Amato, Andrew D Oxman, Pablo Alonso-Coello, Massimo Brunetti, Jenny Moberg, Francesco Nonino, Silvia Pregno, Carlo Saitto, Holger J Schünemann, Marina Davoli
OBJECTIVES: Coverage decisions are decisions by third party payers about whether and how much to pay for technologies or services, and under what conditions. Given their complexity, a systematic and transparent approach is needed. The DECIDE (Developing and Evaluating Communication Strategies to Support Informed Decisions and Practice Based on Evidence) Project, a GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working Group initiative funded by the European Union, has developed GRADE Evidence to Decision (EtD) framework for different types of decisions, including coverage ones...
June 28, 2017: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/28649143/sugar-price-supports-and-taxation-a-public-health-policy-paradox
#19
Abby Dilk, Dennis A Savaiano
Domestic US sugar production has been protected by government policy for the past 82 years, resulting in elevated domestic prices and an estimated annual (2013) $1.4 billion dollar "tax" on consumers. These elevated prices and the simultaneous federal support for domestic corn production have ensured a strong market for high-fructose corn syrup. Americans have dramatically increased their consumption of caloric sweeteners during the same period. Consumption of "empty" calories (ie, foods with low-nutrient/high-caloric density)-sugar and high-fructose corn syrup being the primary sources-is considered by most public health experts to be a key contributing factor to the rise in obesity...
May 2017: Nutrition Today
https://www.readbyqxmd.com/read/28578735/developments-in-value-frameworks-to-inform-the-allocation-of-healthcare-resources
#20
Wija Oortwijn, Laura Sampietro-Colom, Fay Habens
BACKGROUND: In recent years, there has been a surge in the development of frameworks to assess the value of different types of health technologies to inform healthcare resource allocation. The reasons for, and the potential of, these value frameworks were discussed during the 2017 Health Technology Assessment International (HTAi) Policy Forum Meeting. METHODS: This study reflects the discussion, drawing on presentations from invited experts and Policy Forum members, as well as a background paper...
June 5, 2017: International Journal of Technology Assessment in Health Care
keyword
keyword
80684
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"